Stoke Therapeutics Inc is a biotechnology company dedicated to restoring protein expression by harnessing the bodys potential with RNA medicine. Its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, Stoke is developing antisense oligonucleotides (ASOs) to restore naturally-occurring protein levels selectively. Its first medicine in development, zorevunersen, has demonstrated the potential for disease modification in patients with Dravet syndrome. The company provides early programs focused on multiple targets, including haploinsufficiency diseases of the central nervous system and eye, to up-regulate the protein expression of the underlying disease gene in a mutation-agnostic manner.
Last trade$26.32
Day change-$0.31 (-1.16%)
Day range$25.79 – $26.93
Volume197,587
Market cap$1.74B
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$1.74B
Price / earnings
—
Price / book
4.94×
Price / sales
61.74×
EV / sales
57.94×
EV / EBITDA
-6.38×
Profitability
Earnings per share
-$3.72
Return on assets
-59.8%
Return on equity
-68.98%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0×
Current ratio
7.24×
Quick ratio
7.24×
Cash ratio
2.19×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$187.66M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for STOK, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$11.26M
$9.33M
$6.23M
$1.4M
$10.63M
$13.82M
$158.57M
$22.61M
Cost of revenue
$0
$0
$0
$0
$0
$0
$0
$0
Gross profit
$11.26M
$9.33M
$6.23M
$1.4M
$10.63M
$13.82M
$158.57M
$22.61M
Selling, general and administrative
$28.74M
$25.25M
$19.97M
$21.15M
$16.03M
$15.26M
$14.65M
$12.84M
Research and development
$59.83M
$49.5M
$39.67M
$41.7M
$37.7M
$25.86M
$32.68M
$23.42M
Total operating expenses
$88.57M
$74.75M
$59.65M
$62.84M
$53.72M
$41.12M
$47.33M
$36.27M
Operating income
-$77.32M
-$65.43M
-$53.42M
-$61.44M
-$43.09M
-$27.3M
$111.24M
-$13.65M
Interest expense
-$20K
$3.5M
$0
$0
-$3K
$3.79M
$0
$0
Income before taxes
-$73.64M
-$61.62M
-$50M
-$57.93M
-$39.63M
-$23.48M
$114.16M
-$10.48M
Income taxes
$0
$0
$0
$0
-$1.28M
$0
$1.28M
$0
Net income
-$73.64M
-$61.62M
-$50M
-$57.93M
-$38.35M
-$23.48M
$112.88M
-$10.48M
Net income attributable to common shareholders
-$73.64M
-$61.62M
-$50M
-$57.93M
-$38.35M
-$23.48M
$112.88M
-$10.48M
EBITDA
-$76.86M
-$65.43M
-$52.98M
-$61.03M
-$42.65M
-$27.3M
$111.72M
-$13.13M
Basic earnings per share
-$1.08
-$0.93
-$0.79
-$0.93
-$0.65
-$0.40
$1.95
-$0.18
Diluted earnings per share
-$1.08
-$0.93
-$0.79
-$0.96
-$0.65
-$0.40
$1.90
-$0.18
Recent news
Company coverage with links to the original publishers.
Stoke Therapeutics reported a Q3 loss of $1.08 per share, missing consensus estimates of $0.88 loss by 22.73%, though the company exceeded revenue expectations with $11.26 million versus estimated $8.29 million. The stock has underperformed the S&P 500 by 29.9% year-to-date and carries a Zacks Rank #3 (Hold) rating with mixed estimate revisions.
Ratings for Stoke Therapeutics (NASDAQ:STOK) were provided by 5 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.
The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.
Bullish
Somewhat Bullish
Indifferent
Somewhat Bearish
Bearish
Total Ratings
5
0
0
0
0
Last 30D
1
0
0
0
0
1M Ago
0
0
0
0
0
2M Ago
3
0
0
0
0
3M Ago
1
0
0
0
0
Analysts have set 12-month price targets for Stoke Therapeutics, revealing an average target of $24.2, a high estimate of $35.00, and a low estimate of $20.00. Experiencing a 3.2% decline, the current average is now lower than the previous average price target of $25.00.
Understanding Analyst Ratings: A Comprehensive Breakdown
A clear picture of Stoke Therapeutics's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
Analyst
Analyst Firm
Action Taken
Rating
Current Price Target
Prior Price Target
Joseph Stringer
Needham
Maintains
Buy
$22.00
$22.00
Andrew Fein
HC Wainwright & Co.
Maintains
Buy
$35.00
$35.00
Sumant Kulkarni
Canaccord Genuity
Lowers
Buy
$20.00
$21.00
Joseph Stringer
Needham
Maintains
Buy
$22.00
$22.00
Joseph Stringer
Needham
Maintains
Buy
$22.00
-
Key Insights:
Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their ...Full story available on Benzinga.com
Stoke Therapeutics (NASDAQ:STOK) underwent analysis by 8 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
Bullish
Somewhat Bullish
Indifferent
Somewhat Bearish
Bearish
Total Ratings
6
1
1
0
0
Last 30D
1
0
0
0
0
1M Ago
1
0
0
0
0
2M Ago
3
1
1
0
0
3M Ago
1
0
0
0
0
Analysts have recently evaluated Stoke Therapeutics and provided 12-month price targets. The average target is $20.75, accompanied by a high estimate of $35.00 and a low estimate of $13.00. Witnessing a positive shift, the current average has risen by 62.75% from the previous average price target of $12.75.
Understanding Analyst Ratings: A Comprehensive Breakdown
A comprehensive examination of how financial experts perceive Stoke Therapeutics is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
Analyst
Analyst Firm
Action Taken
Rating
Current Price Target
Prior Price Target
Joseph Stringer
Needham
Maintains
Buy
$22.00
-
Joseph Stringer
Needham
Maintains
Buy
$22.00
-
Laura Chico
Wedbush
Raises
Outperform
$17.00
$13.00
Sumant Kulkarni
Canaccord Genuity
Raises
Buy
$21.00
$18.00
Jessica Fye
JP Morgan
Raises
Neutral
$13.00
$6.00
Andrew Fein
HC Wainwright & Co.
Maintains
Buy
$35.00
-
Joseph Stringer
Needham
Raises
Buy
$22.00
$14.00
Joseph Stringer
Needham
Maintains
Buy
$14.00
-
Key Insights:
Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Stoke Therapeutics. This information ...Full story available on Benzinga.com
Stoke Therapeutics (STOK) delivered earnings and revenue surprises of 5% and 26.61%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Axsome (AXSM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.